Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Clinical Trial of PM00104 (Zalypsis®) in Patients With Advanced and/or Metastatic Endometrial or Cervical Cancer Previously Treated With One Line of Systemic Chemotherapy
Phase II Clinical and Pharmacokinetic Trial of PM00104 (Zalypsis®) in Patients With Advanced and/or Metastatic Endometrial or Cervical Cancer Previously Treated With One Line of Systemic Chemotherapy
Status: Archived
Magee-Womens Hospital of UPMC
mi
from
Pittsburgh, PA
Clinical Trial of PM00104 (Zalypsis®) in Patients With Advanced and/or Metastatic Endometrial or Cervical Cancer Previously Treated With One Line of Systemic Chemotherapy
Phase II Clinical and Pharmacokinetic Trial of PM00104 (Zalypsis®) in Patients With Advanced and/or Metastatic Endometrial or Cervical Cancer Previously Treated With One Line of Systemic Chemotherapy
Status: Archived
Updated: 1/1/1970
Magee-Womens Hospital of UPMC
mi
from
Pittsburgh, PA
Clinical Trial of PM00104 (Zalypsis®) in Patients With Advanced and/or Metastatic Endometrial or Cervical Cancer Previously Treated With One Line of Systemic Chemotherapy
Phase II Clinical and Pharmacokinetic Trial of PM00104 (Zalypsis®) in Patients With Advanced and/or Metastatic Endometrial or Cervical Cancer Previously Treated With One Line of Systemic Chemotherapy
Status: Archived
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Clinical Trial of PM00104 (Zalypsis®) in Patients With Advanced and/or Metastatic Endometrial or Cervical Cancer Previously Treated With One Line of Systemic Chemotherapy
Phase II Clinical and Pharmacokinetic Trial of PM00104 (Zalypsis®) in Patients With Advanced and/or Metastatic Endometrial or Cervical Cancer Previously Treated With One Line of Systemic Chemotherapy
Status: Archived
Updated: 1/1/1970
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Azacitidine and Cisplatin in Patients With Advanced Lung or Head and Neck Cancer
Phase I Study of Azacitidine in Combination With Cisplatin in Patients With Recurrent or Metastatic Non-small Cell Lung Cancer or Squamous Cell Carcinoma of the Head and Neck
Status: Archived
Loma Linda Medical Center
mi
from
Loma Linda, CA
Azacitidine and Cisplatin in Patients With Advanced Lung or Head and Neck Cancer
Phase I Study of Azacitidine in Combination With Cisplatin in Patients With Recurrent or Metastatic Non-small Cell Lung Cancer or Squamous Cell Carcinoma of the Head and Neck
Status: Archived
Updated: 1/1/1970
Loma Linda Medical Center
mi
from
Loma Linda, CA
Trial of Fulvestrant, MK-0646, and Dasatinib for Metastatic Hormone Receptor-Positive HER2-Negative Breast Cancer
A Phase I-II, Randomization, Open-Label Clinical Trial of Fulvestrant Versus the Combination of Fulvestrant, MK-0646, and Dasatinib as First-Line Therapy for Metastatic Hormone Receptor-Positive HER2-Negative Breast Cancer
Status: Archived
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Trial of Fulvestrant, MK-0646, and Dasatinib for Metastatic Hormone Receptor-Positive HER2-Negative Breast Cancer
A Phase I-II, Randomization, Open-Label Clinical Trial of Fulvestrant Versus the Combination of Fulvestrant, MK-0646, and Dasatinib as First-Line Therapy for Metastatic Hormone Receptor-Positive HER2-Negative Breast Cancer
Status: Archived
Updated: 1/1/1970
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Riluzole in Women With Stage I, Stage II, or Stage IIIA Breast Cancer
Metabotropic Glutamate Receptor-1 (mGluR1): Validation of a Serendipitously Discovered Molecular Target for Breast Cancer Treatment
Status: Archived
Wayne State University/Detroit Medical Center
mi
from
Detroit, MI
Riluzole in Women With Stage I, Stage II, or Stage IIIA Breast Cancer
Metabotropic Glutamate Receptor-1 (mGluR1): Validation of a Serendipitously Discovered Molecular Target for Breast Cancer Treatment
Status: Archived
Updated: 1/1/1970
Wayne State University/Detroit Medical Center
mi
from
Detroit, MI
Riluzole in Women With Stage I, Stage II, or Stage IIIA Breast Cancer
Metabotropic Glutamate Receptor-1 (mGluR1): Validation of a Serendipitously Discovered Molecular Target for Breast Cancer Treatment
Status: Archived
Sinai-Grace Hospital
mi
from
Detroit, MI
Riluzole in Women With Stage I, Stage II, or Stage IIIA Breast Cancer
Metabotropic Glutamate Receptor-1 (mGluR1): Validation of a Serendipitously Discovered Molecular Target for Breast Cancer Treatment
Status: Archived
Updated: 1/1/1970
Sinai-Grace Hospital
mi
from
Detroit, MI
Observational Study of Subjects Having Routine Recurrence Screening for Bladder Cancer
Phase 3 Study of Bladder Cancer Recurrence Surveillance
Status: Archived
BCG Oncology
mi
from
Phoenix, AZ
Observational Study of Subjects Having Routine Recurrence Screening for Bladder Cancer
Phase 3 Study of Bladder Cancer Recurrence Surveillance
Status: Archived
Updated: 1/1/1970
BCG Oncology
mi
from
Phoenix, AZ
Observational Study of Subjects Having Routine Recurrence Screening for Bladder Cancer
Phase 3 Study of Bladder Cancer Recurrence Surveillance
Status: Archived
Urology Associates
mi
from
, CO
Observational Study of Subjects Having Routine Recurrence Screening for Bladder Cancer
Phase 3 Study of Bladder Cancer Recurrence Surveillance
Status: Archived
Updated: 1/1/1970
Urology Associates
mi
from
, CO
Observational Study of Subjects Having Routine Recurrence Screening for Bladder Cancer
Phase 3 Study of Bladder Cancer Recurrence Surveillance
Status: Archived
Atlantic Urological Associates
mi
from
Daytona Beach, FL
Observational Study of Subjects Having Routine Recurrence Screening for Bladder Cancer
Phase 3 Study of Bladder Cancer Recurrence Surveillance
Status: Archived
Updated: 1/1/1970
Atlantic Urological Associates
mi
from
Daytona Beach, FL
Observational Study of Subjects Having Routine Recurrence Screening for Bladder Cancer
Phase 3 Study of Bladder Cancer Recurrence Surveillance
Status: Archived
Winter Park Urology
mi
from
Orlando, FL
Observational Study of Subjects Having Routine Recurrence Screening for Bladder Cancer
Phase 3 Study of Bladder Cancer Recurrence Surveillance
Status: Archived
Updated: 1/1/1970
Winter Park Urology
mi
from
Orlando, FL
Observational Study of Subjects Having Routine Recurrence Screening for Bladder Cancer
Phase 3 Study of Bladder Cancer Recurrence Surveillance
Status: Archived
Metropolitan Urology
mi
from
Jeffersonville, IN
Observational Study of Subjects Having Routine Recurrence Screening for Bladder Cancer
Phase 3 Study of Bladder Cancer Recurrence Surveillance
Status: Archived
Updated: 1/1/1970
Metropolitan Urology
mi
from
Jeffersonville, IN
Observational Study of Subjects Having Routine Recurrence Screening for Bladder Cancer
Phase 3 Study of Bladder Cancer Recurrence Surveillance
Status: Archived
Mayo Validation Support Services
mi
from
Rochester, MN
Observational Study of Subjects Having Routine Recurrence Screening for Bladder Cancer
Phase 3 Study of Bladder Cancer Recurrence Surveillance
Status: Archived
Updated: 1/1/1970
Mayo Validation Support Services
mi
from
Rochester, MN
Observational Study of Subjects Having Routine Recurrence Screening for Bladder Cancer
Phase 3 Study of Bladder Cancer Recurrence Surveillance
Status: Archived
Metro Urology
mi
from
Woodbury, MN
Observational Study of Subjects Having Routine Recurrence Screening for Bladder Cancer
Phase 3 Study of Bladder Cancer Recurrence Surveillance
Status: Archived
Updated: 1/1/1970
Metro Urology
mi
from
Woodbury, MN
Observational Study of Subjects Having Routine Recurrence Screening for Bladder Cancer
Phase 3 Study of Bladder Cancer Recurrence Surveillance
Status: Archived
Associates in Urology/Urology Group of NJ
mi
from
West Orange, NJ
Observational Study of Subjects Having Routine Recurrence Screening for Bladder Cancer
Phase 3 Study of Bladder Cancer Recurrence Surveillance
Status: Archived
Updated: 1/1/1970
Associates in Urology/Urology Group of NJ
mi
from
West Orange, NJ
Observational Study of Subjects Having Routine Recurrence Screening for Bladder Cancer
Phase 3 Study of Bladder Cancer Recurrence Surveillance
Status: Archived
Coastal Urology Associates
mi
from
Brick, NJ
Observational Study of Subjects Having Routine Recurrence Screening for Bladder Cancer
Phase 3 Study of Bladder Cancer Recurrence Surveillance
Status: Archived
Updated: 1/1/1970
Coastal Urology Associates
mi
from
Brick, NJ
Observational Study of Subjects Having Routine Recurrence Screening for Bladder Cancer
Phase 3 Study of Bladder Cancer Recurrence Surveillance
Status: Archived
Community Care Physicians
mi
from
Albany, NY
Observational Study of Subjects Having Routine Recurrence Screening for Bladder Cancer
Phase 3 Study of Bladder Cancer Recurrence Surveillance
Status: Archived
Updated: 1/1/1970
Community Care Physicians
mi
from
Albany, NY
Observational Study of Subjects Having Routine Recurrence Screening for Bladder Cancer
Phase 3 Study of Bladder Cancer Recurrence Surveillance
Status: Archived
Capital Regional Urological Surgeons
mi
from
Albany, NY
Observational Study of Subjects Having Routine Recurrence Screening for Bladder Cancer
Phase 3 Study of Bladder Cancer Recurrence Surveillance
Status: Archived
Updated: 1/1/1970
Capital Regional Urological Surgeons
mi
from
Albany, NY
Observational Study of Subjects Having Routine Recurrence Screening for Bladder Cancer
Phase 3 Study of Bladder Cancer Recurrence Surveillance
Status: Archived
University Urology Associates
mi
from
, NY
Observational Study of Subjects Having Routine Recurrence Screening for Bladder Cancer
Phase 3 Study of Bladder Cancer Recurrence Surveillance
Status: Archived
Updated: 1/1/1970
University Urology Associates
mi
from
, NY
Observational Study of Subjects Having Routine Recurrence Screening for Bladder Cancer
Phase 3 Study of Bladder Cancer Recurrence Surveillance
Status: Archived
Hudson Valley Urology
mi
from
Poughkeepsie, NY
Observational Study of Subjects Having Routine Recurrence Screening for Bladder Cancer
Phase 3 Study of Bladder Cancer Recurrence Surveillance
Status: Archived
Updated: 1/1/1970
Hudson Valley Urology
mi
from
Poughkeepsie, NY
Observational Study of Subjects Having Routine Recurrence Screening for Bladder Cancer
Phase 3 Study of Bladder Cancer Recurrence Surveillance
Status: Archived
Associated Medical Professionals
mi
from
Syracuse, NY
Observational Study of Subjects Having Routine Recurrence Screening for Bladder Cancer
Phase 3 Study of Bladder Cancer Recurrence Surveillance
Status: Archived
Updated: 1/1/1970
Associated Medical Professionals
mi
from
Syracuse, NY
Observational Study of Subjects Having Routine Recurrence Screening for Bladder Cancer
Phase 3 Study of Bladder Cancer Recurrence Surveillance
Status: Archived
The Urology Group
mi
from
Cinncinnatti, OH
Observational Study of Subjects Having Routine Recurrence Screening for Bladder Cancer
Phase 3 Study of Bladder Cancer Recurrence Surveillance
Status: Archived
Updated: 1/1/1970
The Urology Group
mi
from
Cinncinnatti, OH
Observational Study of Subjects Having Routine Recurrence Screening for Bladder Cancer
Phase 3 Study of Bladder Cancer Recurrence Surveillance
Status: Archived
Urological Associates of Lancaster
mi
from
Lancaster, PA
Observational Study of Subjects Having Routine Recurrence Screening for Bladder Cancer
Phase 3 Study of Bladder Cancer Recurrence Surveillance
Status: Archived
Updated: 1/1/1970
Urological Associates of Lancaster
mi
from
Lancaster, PA
Observational Study of Subjects Having Routine Recurrence Screening for Bladder Cancer
Phase 3 Study of Bladder Cancer Recurrence Surveillance
Status: Archived
Triangle Urologic Group
mi
from
Pittsburgh, PA
Observational Study of Subjects Having Routine Recurrence Screening for Bladder Cancer
Phase 3 Study of Bladder Cancer Recurrence Surveillance
Status: Archived
Updated: 1/1/1970
Triangle Urologic Group
mi
from
Pittsburgh, PA
Observational Study of Subjects Having Routine Recurrence Screening for Bladder Cancer
Phase 3 Study of Bladder Cancer Recurrence Surveillance
Status: Archived
Carolina Urologic Research Center
mi
from
Myrtle Beach, SC
Observational Study of Subjects Having Routine Recurrence Screening for Bladder Cancer
Phase 3 Study of Bladder Cancer Recurrence Surveillance
Status: Archived
Updated: 1/1/1970
Carolina Urologic Research Center
mi
from
Myrtle Beach, SC
Observational Study of Subjects Having Routine Recurrence Screening for Bladder Cancer
Phase 3 Study of Bladder Cancer Recurrence Surveillance
Status: Archived
Urology Clinics of North Texas
mi
from
Dallas, TX
Observational Study of Subjects Having Routine Recurrence Screening for Bladder Cancer
Phase 3 Study of Bladder Cancer Recurrence Surveillance
Status: Archived
Updated: 1/1/1970
Urology Clinics of North Texas
mi
from
Dallas, TX
Observational Study of Subjects Having Routine Recurrence Screening for Bladder Cancer
Phase 3 Study of Bladder Cancer Recurrence Surveillance
Status: Archived
Urology San Antonio
mi
from
San Antonio, TX
Observational Study of Subjects Having Routine Recurrence Screening for Bladder Cancer
Phase 3 Study of Bladder Cancer Recurrence Surveillance
Status: Archived
Updated: 1/1/1970
Urology San Antonio
mi
from
San Antonio, TX
Eltrombopag Treatment of Thrombocytopenia in Subjects With Advanced Myelodysplastic Syndrome (MDS) or Secondary Acute Myeloid Leukemia After MDS (sAML/MDS)
Study PMA112509, a Phase I/II Study of Eltrombopag in Thrombocytopenic Subjects With Advanced Myelodysplastic Syndrome (MDS) or Secondary Acute Myeloid Leukemia After MDS (sAML/MDS)
Status: Archived
GSK Investigational Site
mi
from
Anaheim, CA
Eltrombopag Treatment of Thrombocytopenia in Subjects With Advanced Myelodysplastic Syndrome (MDS) or Secondary Acute Myeloid Leukemia After MDS (sAML/MDS)
Study PMA112509, a Phase I/II Study of Eltrombopag in Thrombocytopenic Subjects With Advanced Myelodysplastic Syndrome (MDS) or Secondary Acute Myeloid Leukemia After MDS (sAML/MDS)
Status: Archived
Updated: 1/1/1970
GSK Investigational Site
mi
from
Anaheim, CA
Eltrombopag Treatment of Thrombocytopenia in Subjects With Advanced Myelodysplastic Syndrome (MDS) or Secondary Acute Myeloid Leukemia After MDS (sAML/MDS)
Study PMA112509, a Phase I/II Study of Eltrombopag in Thrombocytopenic Subjects With Advanced Myelodysplastic Syndrome (MDS) or Secondary Acute Myeloid Leukemia After MDS (sAML/MDS)
Status: Archived
Yale University School of Medicine
mi
from
New Haven, CT
Eltrombopag Treatment of Thrombocytopenia in Subjects With Advanced Myelodysplastic Syndrome (MDS) or Secondary Acute Myeloid Leukemia After MDS (sAML/MDS)
Study PMA112509, a Phase I/II Study of Eltrombopag in Thrombocytopenic Subjects With Advanced Myelodysplastic Syndrome (MDS) or Secondary Acute Myeloid Leukemia After MDS (sAML/MDS)
Status: Archived
Updated: 1/1/1970
Yale University School of Medicine
mi
from
New Haven, CT
Eltrombopag Treatment of Thrombocytopenia in Subjects With Advanced Myelodysplastic Syndrome (MDS) or Secondary Acute Myeloid Leukemia After MDS (sAML/MDS)
Study PMA112509, a Phase I/II Study of Eltrombopag in Thrombocytopenic Subjects With Advanced Myelodysplastic Syndrome (MDS) or Secondary Acute Myeloid Leukemia After MDS (sAML/MDS)
Status: Archived
Hospital of the University of Pennsylvania
mi
from
Philadelphia, PA
Eltrombopag Treatment of Thrombocytopenia in Subjects With Advanced Myelodysplastic Syndrome (MDS) or Secondary Acute Myeloid Leukemia After MDS (sAML/MDS)
Study PMA112509, a Phase I/II Study of Eltrombopag in Thrombocytopenic Subjects With Advanced Myelodysplastic Syndrome (MDS) or Secondary Acute Myeloid Leukemia After MDS (sAML/MDS)
Status: Archived
Updated: 1/1/1970
Hospital of the University of Pennsylvania
mi
from
Philadelphia, PA
Eltrombopag Treatment of Thrombocytopenia in Subjects With Advanced Myelodysplastic Syndrome (MDS) or Secondary Acute Myeloid Leukemia After MDS (sAML/MDS)
Study PMA112509, a Phase I/II Study of Eltrombopag in Thrombocytopenic Subjects With Advanced Myelodysplastic Syndrome (MDS) or Secondary Acute Myeloid Leukemia After MDS (sAML/MDS)
Status: Archived
GSK Investigational Site
mi
from
Grand Rapids, MI
Eltrombopag Treatment of Thrombocytopenia in Subjects With Advanced Myelodysplastic Syndrome (MDS) or Secondary Acute Myeloid Leukemia After MDS (sAML/MDS)
Study PMA112509, a Phase I/II Study of Eltrombopag in Thrombocytopenic Subjects With Advanced Myelodysplastic Syndrome (MDS) or Secondary Acute Myeloid Leukemia After MDS (sAML/MDS)
Status: Archived
Updated: 1/1/1970
GSK Investigational Site
mi
from
Grand Rapids, MI
Eltrombopag Treatment of Thrombocytopenia in Subjects With Advanced Myelodysplastic Syndrome (MDS) or Secondary Acute Myeloid Leukemia After MDS (sAML/MDS)
Study PMA112509, a Phase I/II Study of Eltrombopag in Thrombocytopenic Subjects With Advanced Myelodysplastic Syndrome (MDS) or Secondary Acute Myeloid Leukemia After MDS (sAML/MDS)
Status: Archived
GSK Investigational Site
mi
from
Chesterfield, MO
Eltrombopag Treatment of Thrombocytopenia in Subjects With Advanced Myelodysplastic Syndrome (MDS) or Secondary Acute Myeloid Leukemia After MDS (sAML/MDS)
Study PMA112509, a Phase I/II Study of Eltrombopag in Thrombocytopenic Subjects With Advanced Myelodysplastic Syndrome (MDS) or Secondary Acute Myeloid Leukemia After MDS (sAML/MDS)
Status: Archived
Updated: 1/1/1970
GSK Investigational Site
mi
from
Chesterfield, MO
Eltrombopag Treatment of Thrombocytopenia in Subjects With Advanced Myelodysplastic Syndrome (MDS) or Secondary Acute Myeloid Leukemia After MDS (sAML/MDS)
Study PMA112509, a Phase I/II Study of Eltrombopag in Thrombocytopenic Subjects With Advanced Myelodysplastic Syndrome (MDS) or Secondary Acute Myeloid Leukemia After MDS (sAML/MDS)
Status: Archived
GSK Investigational Site
mi
from
Cherry Hill, NJ
Eltrombopag Treatment of Thrombocytopenia in Subjects With Advanced Myelodysplastic Syndrome (MDS) or Secondary Acute Myeloid Leukemia After MDS (sAML/MDS)
Study PMA112509, a Phase I/II Study of Eltrombopag in Thrombocytopenic Subjects With Advanced Myelodysplastic Syndrome (MDS) or Secondary Acute Myeloid Leukemia After MDS (sAML/MDS)
Status: Archived
Updated: 1/1/1970
GSK Investigational Site
mi
from
Cherry Hill, NJ
Eltrombopag Treatment of Thrombocytopenia in Subjects With Advanced Myelodysplastic Syndrome (MDS) or Secondary Acute Myeloid Leukemia After MDS (sAML/MDS)
Study PMA112509, a Phase I/II Study of Eltrombopag in Thrombocytopenic Subjects With Advanced Myelodysplastic Syndrome (MDS) or Secondary Acute Myeloid Leukemia After MDS (sAML/MDS)
Status: Archived
West Virginia University Hospitals Inc.
mi
from
Morgantown, WV
Eltrombopag Treatment of Thrombocytopenia in Subjects With Advanced Myelodysplastic Syndrome (MDS) or Secondary Acute Myeloid Leukemia After MDS (sAML/MDS)
Study PMA112509, a Phase I/II Study of Eltrombopag in Thrombocytopenic Subjects With Advanced Myelodysplastic Syndrome (MDS) or Secondary Acute Myeloid Leukemia After MDS (sAML/MDS)
Status: Archived
Updated: 1/1/1970
West Virginia University Hospitals Inc.
mi
from
Morgantown, WV
Eltrombopag Treatment of Thrombocytopenia in Subjects With Advanced Myelodysplastic Syndrome (MDS) or Secondary Acute Myeloid Leukemia After MDS (sAML/MDS)
Study PMA112509, a Phase I/II Study of Eltrombopag in Thrombocytopenic Subjects With Advanced Myelodysplastic Syndrome (MDS) or Secondary Acute Myeloid Leukemia After MDS (sAML/MDS)
Status: Archived
GSK Investigational Site
mi
from
Philadelphia, PA
Eltrombopag Treatment of Thrombocytopenia in Subjects With Advanced Myelodysplastic Syndrome (MDS) or Secondary Acute Myeloid Leukemia After MDS (sAML/MDS)
Study PMA112509, a Phase I/II Study of Eltrombopag in Thrombocytopenic Subjects With Advanced Myelodysplastic Syndrome (MDS) or Secondary Acute Myeloid Leukemia After MDS (sAML/MDS)
Status: Archived
Updated: 1/1/1970
GSK Investigational Site
mi
from
Philadelphia, PA
Eltrombopag Treatment of Thrombocytopenia in Subjects With Advanced Myelodysplastic Syndrome (MDS) or Secondary Acute Myeloid Leukemia After MDS (sAML/MDS)
Study PMA112509, a Phase I/II Study of Eltrombopag in Thrombocytopenic Subjects With Advanced Myelodysplastic Syndrome (MDS) or Secondary Acute Myeloid Leukemia After MDS (sAML/MDS)
Status: Archived
GSK Investigational Site
mi
from
Knoxville, TN
Eltrombopag Treatment of Thrombocytopenia in Subjects With Advanced Myelodysplastic Syndrome (MDS) or Secondary Acute Myeloid Leukemia After MDS (sAML/MDS)
Study PMA112509, a Phase I/II Study of Eltrombopag in Thrombocytopenic Subjects With Advanced Myelodysplastic Syndrome (MDS) or Secondary Acute Myeloid Leukemia After MDS (sAML/MDS)
Status: Archived
Updated: 1/1/1970
GSK Investigational Site
mi
from
Knoxville, TN
Eltrombopag Treatment of Thrombocytopenia in Subjects With Advanced Myelodysplastic Syndrome (MDS) or Secondary Acute Myeloid Leukemia After MDS (sAML/MDS)
Study PMA112509, a Phase I/II Study of Eltrombopag in Thrombocytopenic Subjects With Advanced Myelodysplastic Syndrome (MDS) or Secondary Acute Myeloid Leukemia After MDS (sAML/MDS)
Status: Archived
GSK Investigational Site
mi
from
Austin, TX
Eltrombopag Treatment of Thrombocytopenia in Subjects With Advanced Myelodysplastic Syndrome (MDS) or Secondary Acute Myeloid Leukemia After MDS (sAML/MDS)
Study PMA112509, a Phase I/II Study of Eltrombopag in Thrombocytopenic Subjects With Advanced Myelodysplastic Syndrome (MDS) or Secondary Acute Myeloid Leukemia After MDS (sAML/MDS)
Status: Archived
Updated: 1/1/1970
GSK Investigational Site
mi
from
Austin, TX
Eltrombopag Treatment of Thrombocytopenia in Subjects With Advanced Myelodysplastic Syndrome (MDS) or Secondary Acute Myeloid Leukemia After MDS (sAML/MDS)
Study PMA112509, a Phase I/II Study of Eltrombopag in Thrombocytopenic Subjects With Advanced Myelodysplastic Syndrome (MDS) or Secondary Acute Myeloid Leukemia After MDS (sAML/MDS)
Status: Archived
GSK Investigational Site
mi
from
Richmond, VA
Eltrombopag Treatment of Thrombocytopenia in Subjects With Advanced Myelodysplastic Syndrome (MDS) or Secondary Acute Myeloid Leukemia After MDS (sAML/MDS)
Study PMA112509, a Phase I/II Study of Eltrombopag in Thrombocytopenic Subjects With Advanced Myelodysplastic Syndrome (MDS) or Secondary Acute Myeloid Leukemia After MDS (sAML/MDS)
Status: Archived
Updated: 1/1/1970
GSK Investigational Site
mi
from
Richmond, VA
Surgery and Oxaliplatin or Mitomycin C in Treating Patients With Primary Colorectal Tumors or Tumors of the Appendix
A Multi-Center, Open-Label, Randomized Phase II Trial to Evaluate Hematologic Toxicities After IPHC With Oxaliplatin or Mitomycin C in Patients With Primary Colorectal or Appendiceal Tumors
Status: Archived
Wake Forest University Baptist Medical Center
mi
from
Winston-Salem, NC
Surgery and Oxaliplatin or Mitomycin C in Treating Patients With Primary Colorectal Tumors or Tumors of the Appendix
A Multi-Center, Open-Label, Randomized Phase II Trial to Evaluate Hematologic Toxicities After IPHC With Oxaliplatin or Mitomycin C in Patients With Primary Colorectal or Appendiceal Tumors
Status: Archived
Updated: 1/1/1970
Wake Forest University Baptist Medical Center
mi
from
Winston-Salem, NC
Surgery and Oxaliplatin or Mitomycin C in Treating Patients With Primary Colorectal Tumors or Tumors of the Appendix
A Multi-Center, Open-Label, Randomized Phase II Trial to Evaluate Hematologic Toxicities After IPHC With Oxaliplatin or Mitomycin C in Patients With Primary Colorectal or Appendiceal Tumors
Status: Archived
University of Pittsburgh, Emergency Responder Human Performance Lab
mi
from
Pittsburgh, PA
Surgery and Oxaliplatin or Mitomycin C in Treating Patients With Primary Colorectal Tumors or Tumors of the Appendix
A Multi-Center, Open-Label, Randomized Phase II Trial to Evaluate Hematologic Toxicities After IPHC With Oxaliplatin or Mitomycin C in Patients With Primary Colorectal or Appendiceal Tumors
Status: Archived
Updated: 1/1/1970
University of Pittsburgh, Emergency Responder Human Performance Lab
mi
from
Pittsburgh, PA
Surgery and Oxaliplatin or Mitomycin C in Treating Patients With Primary Colorectal Tumors or Tumors of the Appendix
A Multi-Center, Open-Label, Randomized Phase II Trial to Evaluate Hematologic Toxicities After IPHC With Oxaliplatin or Mitomycin C in Patients With Primary Colorectal or Appendiceal Tumors
Status: Archived
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Surgery and Oxaliplatin or Mitomycin C in Treating Patients With Primary Colorectal Tumors or Tumors of the Appendix
A Multi-Center, Open-Label, Randomized Phase II Trial to Evaluate Hematologic Toxicities After IPHC With Oxaliplatin or Mitomycin C in Patients With Primary Colorectal or Appendiceal Tumors
Status: Archived
Updated: 1/1/1970
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Ph I/II of Vitamin D on Bone Mineral Density & Markers of Bone Resorption
A Phase I/II Randomized, Double-blind, Controlled Study to Evaluate Efficacy and Safety of Vitamin D on Bone Mineral Density and Markers of Bone Resorption in Aromatase Inhibitor-induced Bone Loss in Women With Breast Cancer.
Status: Archived
Stanford university Hospital and Clinics
mi
from
Stanford, CA
Ph I/II of Vitamin D on Bone Mineral Density & Markers of Bone Resorption
A Phase I/II Randomized, Double-blind, Controlled Study to Evaluate Efficacy and Safety of Vitamin D on Bone Mineral Density and Markers of Bone Resorption in Aromatase Inhibitor-induced Bone Loss in Women With Breast Cancer.
Status: Archived
Updated: 1/1/1970
Stanford university Hospital and Clinics
mi
from
Stanford, CA
Treatment of Advanced Head and Neck Cancer With Opioid Growth Factor
Treatment of Advanced Head and Neck Cancer With Opioid Growth Factor: Phase II
Status: Archived
Penn State Milton S. Hershey Medical Center
mi
from
Hershey, PA
Treatment of Advanced Head and Neck Cancer With Opioid Growth Factor
Treatment of Advanced Head and Neck Cancer With Opioid Growth Factor: Phase II
Status: Archived
Updated: 1/1/1970
Penn State Milton S. Hershey Medical Center
mi
from
Hershey, PA
A Phase I/II Open-Label Dose-Escalation Clinical Trial of CPI-613 in Combination With Gemcitabine in Cancer Patients
A Phase I/II Open-Label Dose-Escalation Clinical Trial of CPI-613 in Combination With Gemcitabine in Cancer Patients
Status: Archived
East-West Medical Research Institute
mi
from
Honolulu, HI
A Phase I/II Open-Label Dose-Escalation Clinical Trial of CPI-613 in Combination With Gemcitabine in Cancer Patients
A Phase I/II Open-Label Dose-Escalation Clinical Trial of CPI-613 in Combination With Gemcitabine in Cancer Patients
Status: Archived
Updated: 1/1/1970
East-West Medical Research Institute
mi
from
Honolulu, HI
A Phase I/II Open-Label Dose-Escalation Clinical Trial of CPI-613 in Combination With Gemcitabine in Cancer Patients
A Phase I/II Open-Label Dose-Escalation Clinical Trial of CPI-613 in Combination With Gemcitabine in Cancer Patients
Status: Archived
Mary Crowley Cancer Research Center
mi
from
Dallas, TX
A Phase I/II Open-Label Dose-Escalation Clinical Trial of CPI-613 in Combination With Gemcitabine in Cancer Patients
A Phase I/II Open-Label Dose-Escalation Clinical Trial of CPI-613 in Combination With Gemcitabine in Cancer Patients
Status: Archived
Updated: 1/1/1970
Mary Crowley Cancer Research Center
mi
from
Dallas, TX
A Study of Bevacizumab to Prevent Malignant Ascites
A Prospective, Phase II Trial of Intravenous Bevacizumab (Avastin) for the Prevention of Recurrent Malignant Ascites
Status: Archived
Baylor School of Medicine
mi
from
Houston, TX
A Study of Bevacizumab to Prevent Malignant Ascites
A Prospective, Phase II Trial of Intravenous Bevacizumab (Avastin) for the Prevention of Recurrent Malignant Ascites
Status: Archived
Updated: 1/1/1970
Baylor School of Medicine
mi
from
Houston, TX
A Study of Bevacizumab to Prevent Malignant Ascites
A Prospective, Phase II Trial of Intravenous Bevacizumab (Avastin) for the Prevention of Recurrent Malignant Ascites
Status: Archived
Ben Taub General Hospital
mi
from
Houston, TX
A Study of Bevacizumab to Prevent Malignant Ascites
A Prospective, Phase II Trial of Intravenous Bevacizumab (Avastin) for the Prevention of Recurrent Malignant Ascites
Status: Archived
Updated: 1/1/1970
Ben Taub General Hospital
mi
from
Houston, TX
A Study of Bevacizumab to Prevent Malignant Ascites
A Prospective, Phase II Trial of Intravenous Bevacizumab (Avastin) for the Prevention of Recurrent Malignant Ascites
Status: Archived
Veterans Affairs Medical Center - East Orange
mi
from
East Orange, NJ
A Study of Bevacizumab to Prevent Malignant Ascites
A Prospective, Phase II Trial of Intravenous Bevacizumab (Avastin) for the Prevention of Recurrent Malignant Ascites
Status: Archived
Updated: 1/1/1970
Veterans Affairs Medical Center - East Orange
mi
from
East Orange, NJ
Vaccine Therapy in Treating Patients With Progressive Stage D0 Prostate Cancer
A Pilot Study of Vaccination With Epitope-Enhanced TARP Peptide and TARP Peptide-Pulsed Dendritic Cells in the Treatment of Stage D0 Prostate Cancer
Status: Archived
National Cancer Institute (NCI)
mi
from
Bethesda, MD
Vaccine Therapy in Treating Patients With Progressive Stage D0 Prostate Cancer
A Pilot Study of Vaccination With Epitope-Enhanced TARP Peptide and TARP Peptide-Pulsed Dendritic Cells in the Treatment of Stage D0 Prostate Cancer
Status: Archived
Updated: 1/1/1970
National Cancer Institute (NCI)
mi
from
Bethesda, MD
A Study of BMS-833923 With Cisplatin and Capecitabine in Inoperable, Metastatic Gastric, Gastroesophageal, or Esophageal Adenocarcinomas
Phase 1b Multiple Ascending Dose Study of BMS-833923 (XL139) Administered in Combination With Cisplatin and Capecitabine as First-Line Therapy in Patients With Inoperable, Metastatic Gastric, Gastroesophageal, or Esophageal Adenocarcinomas
Status: Archived
City of Hope National Medical Center
mi
from
Duarte, CA
A Study of BMS-833923 With Cisplatin and Capecitabine in Inoperable, Metastatic Gastric, Gastroesophageal, or Esophageal Adenocarcinomas
Phase 1b Multiple Ascending Dose Study of BMS-833923 (XL139) Administered in Combination With Cisplatin and Capecitabine as First-Line Therapy in Patients With Inoperable, Metastatic Gastric, Gastroesophageal, or Esophageal Adenocarcinomas
Status: Archived
Updated: 1/1/1970
City of Hope National Medical Center
mi
from
Duarte, CA
A Study of BMS-833923 With Cisplatin and Capecitabine in Inoperable, Metastatic Gastric, Gastroesophageal, or Esophageal Adenocarcinomas
Phase 1b Multiple Ascending Dose Study of BMS-833923 (XL139) Administered in Combination With Cisplatin and Capecitabine as First-Line Therapy in Patients With Inoperable, Metastatic Gastric, Gastroesophageal, or Esophageal Adenocarcinomas
Status: Archived
U.S.C./Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
A Study of BMS-833923 With Cisplatin and Capecitabine in Inoperable, Metastatic Gastric, Gastroesophageal, or Esophageal Adenocarcinomas
Phase 1b Multiple Ascending Dose Study of BMS-833923 (XL139) Administered in Combination With Cisplatin and Capecitabine as First-Line Therapy in Patients With Inoperable, Metastatic Gastric, Gastroesophageal, or Esophageal Adenocarcinomas
Status: Archived
Updated: 1/1/1970
U.S.C./Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA